The folding of alpha-1-proteinase inhibitor: Kinetic vs equilibrium control

被引:6
作者
Tran, ST [1 ]
Shrake, A [1 ]
机构
[1] US FDA, Div Hematol, Off Blood Res & Rev, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
关键词
alpha-1-proteinase inhibitor; alpha-1; antitrypsin; serine protease inhibitor; protein folding; kinetically controlled protein folding; equilibrium controlled protein folding; guanidine-HC1-induced protein unfolding/refolding;
D O I
10.1006/abbi.2000.2186
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous folding studies of alpha -1-proteinase inhibitor (alpha (1)-PI), which regulates the activity of the serine protease human neutrophil elastase, show an intermediate state at similar to1.5 M guanidine-HCl (Gu), For the normal form of alpha (1)-PI, we demonstrate the reversible formation of the same stable distribution of monomeric and polymeric intermediates after similar to1 h in 1.5 M Gu at similar to 23 degreesC from fully folded or fully unfolded alpha (1)-PI at similar final total concentrations and show that the stable distribution of monomeric and polymeric intermediates conforms with the law of mass action. We attribute these observations to an apparent equilibrium among intermediates. Our CD data are compatible with the intermediates having slightly relaxed structures relative to that of fully folded alpha (1)-PI and, thus, with the polymeric intermediates having a loop-sheet structure. Furthermore, we observe that the rates of folding (fast and slow terms) from the intermediate state are the same as those from the fully unfolded state, thereby supporting the contention that this intermediate state is on the folding pathway. We attribute the tendency of the Z mutant protein to polymerize/aggregate to an increased rate of the monomeric intermediate to form the apparent equilibrium distribution of intermediate species relative to its rate of folding to give intact alpha (1)-PI. (C) 2001 Academic Press.
引用
收藏
页码:322 / 331
页数:10
相关论文
共 44 条
[1]   KINETICS VERSUS THERMODYNAMICS IN PROTEIN-FOLDING [J].
BAKER, D ;
AGARD, DA .
BIOCHEMISTRY, 1994, 33 (24) :7505-7509
[2]  
BEATTY K, 1980, J BIOL CHEM, V255, P3931
[3]  
BRANTLY M, 1988, AM J MED, V84, P13
[4]  
BRUCH M, 1988, J BIOL CHEM, V263, P16626
[5]   STRUCTURE AND VARIATION OF HUMAN ALPHA-1-ANTITRYPSIN [J].
CARRELL, RW ;
JEPPSSON, JO ;
LAURELL, CB ;
BRENNAN, SO ;
OWEN, MC ;
VAUGHAN, L ;
BOSWELL, DR .
NATURE, 1982, 298 (5872) :329-334
[6]   HUMAN ALPHA-1-ANTITRYPSIN - CARBOHYDRATE ATTACHMENT AND SEQUENCE HOMOLOGY [J].
CARRELL, RW ;
JEPPSSON, JO ;
VAUGHAN, L ;
BRENNAN, SO ;
OWEN, MC ;
BOSWELL, DR .
FEBS LETTERS, 1981, 135 (02) :301-303
[7]  
CARRELL RW, 1994, AM J RESP CRIT CARE, V150, P171
[8]   P-NITROPHENYL-P'-GUANIDINOBENZOATE HCL - A NEW ACTIVE SITE TITRANT FOR TRYPSIN [J].
CHASE, T ;
SHAW, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 29 (04) :508-&
[9]   AGGREGATION OF PLASMA-Z TYPE ALPHA-1-ANTITRYPSIN SUGGESTS BASIC DEFECT FOR THE DEFICIENCY [J].
COX, DW ;
BILLINGSLEY, GD ;
CALLAHAN, JW .
FEBS LETTERS, 1986, 205 (02) :255-260
[10]   ALPHA-1-ANTITRYPSIN DEFICIENCY, EMPHYSEMA, AND LIVER-DISEASE - GENETIC-BASIS AND STRATEGIES FOR THERAPY [J].
CRYSTAL, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1343-1352